Thursday, 25 April 2013

Moving Round the Drug Monopoly Board

#MSresearch #MS Blog New drug for spasticity
Canbex Therapeutics Ltd has completed a £2.1m ($3.2m) fundraising round that will enable the Company to complete the early development of its lead candidate for the treatment of spasticity in multiple sclerosis (MS). Merck Serono Ventures, the venture capital arm of Merck Serono, led the financing for this round.

Canbex Therapeutics Ltd is a University spin-out founded by a scientific team including Prof B and Professor David Selwood and later joined by Prof G. The company received a Translation Award from the Wellcome Trust, which was stimulated by support from Fast Forward from the USA, to underpin development of their lead candidate.
Phase I here we come with a drug that is safe as houses.

CoI: Prof B and G and MD2 have shares in this company. 


Please note that all comments are moderated and any personal or marketing-related submissions will not be shown.